Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 4,169,700 | 1,399,400 | 1,521,900 | 1,503,100 | 823,400 |
| Depreciation Amortization | 155,200 | 144,900 | 139,600 | 134,800 | 107,200 |
| Income taxes - deferred | -323,400 | -272,100 | -254,500 | -41,400 | -49,400 |
| Accounts receivable | 121,200 | -141,200 | -84,100 | -91,100 | 41,900 |
| Other Working Capital | -259,300 | -526,300 | -421,400 | 174,500 | -228,300 |
| Other Operating Activity | -3,321,100 | 291,100 | 316,700 | 52,200 | 359,500 |
| Operating Cash Flow | $542,300 | $895,800 | $1,218,200 | $1,732,100 | $1,054,300 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -252,400 | -253,000 | -244,600 | -325,800 | -407,000 |
| Net Acquisitions | -1,108,000 | -125,200 | -109,600 | -13,100 | -10,000 |
| Purchase Of Investment | -945,800 | -75,500 | -669,300 | -1,879,300 | -851,700 |
| Sale Of Investment | 4,785,000 | 715,800 | 1,359,100 | 529,200 | 777,000 |
| Purchase Sale Intangibles | -30,000 | -13,300 | -20,200 | -4,000 | -300 |
| Other Investing Activity | -165,900 | -88,300 | -83,300 | -33,500 | -39,400 |
| Investing Cash Flow | $2,312,900 | $173,800 | $252,300 | $-1,722,500 | $-531,100 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 5,200 | 16,200 |
| Debt Repayment | N/A | N/A | N/A | -7,000 | -17,000 |
| Common Stock Issued | 179,500 | 169,900 | 146,400 | N/A | 140,500 |
| Common Stock Repurchased | -1,159,400 | -879,600 | -1,727,100 | -512,800 | -625,400 |
| Other Financing Activity | -3,100 | -1,300 | -3,800 | 158,300 | -1,200 |
| Financing Cash Flow | $-983,000 | $-711,000 | $-1,584,500 | $-356,300 | $-486,900 |
| Exchange Rate Effect | 38,600 | 16,800 | 19,200 | 13,900 | -20,500 |
| Beginning Cash Position | 1,148,000 | 772,600 | 867,400 | 1,200,200 | 1,184,400 |
| End Cash Position | 3,058,800 | 1,148,000 | 772,600 | 867,400 | 1,200,200 |
| Net Cash Flow | $1,910,800 | $375,400 | $-94,800 | $-332,800 | $15,800 |
| Free Cash Flow | |||||
| Operating Cash Flow | 542,300 | 895,800 | 1,218,200 | 1,732,100 | 1,054,300 |
| Capital Expenditure | -252,400 | -253,000 | -244,600 | -325,800 | -407,000 |
| Free Cash Flow | 289,900 | 642,800 | 973,600 | 1,406,300 | 647,300 |